💙 🔷 Not impressed by Big Tech in Q3? Explore these Blue Chip Bargains insteadUnlock them all

Philips and Bon Secours announce patient monitoring deal

EditorNatashya Angelica
Published 17/07/2024, 18:30
PHG
-

AMSTERDAM & CINCINNATI - Royal Philips (LON:0LNG) (NYSE: PHG, AEX: PHIA), a health technology company, and Bon Secours Mercy Health (BSMH), a large Catholic health system, have entered a multi-year strategic collaboration to enhance patient monitoring capabilities across BSMH's network. The partnership aims to provide BSMH clinicians with advanced tools to reduce digital workload and increase time for patient care.

The agreement will offer access to Philips' latest patient monitoring technologies and will standardize patient monitoring across BSMH's 49 hospitals. This standardization is expected to cut costs through a predictable payment model and promote further investment in healthcare innovation.

Implementation of the new patient monitoring platform will take place over the next three years, with an additional seven years dedicated to maintenance and updates. BSMH operates a network of more than 1,200 care sites, including 49 hospitals, and provides care more than 11 million times annually in states like Florida, Kentucky, Maryland, New York, Ohio, South Carolina, and Virginia, as well as in Ireland.

Jodi Pahl, Chief Nursing Officer for workforce experience and nursing outcomes at Bon Secours Mercy Health, expressed that the collaboration is aligned with BSMH's mission to improve community health and supports its commitment to innovation. Philips' Chief Business Leader of Connected Care, Julia Strandberg, highlighted the partnership's focus on enhancing both patient and staff experiences by leveraging technology to improve clinical outcomes.

This strategic collaboration is part of a broader commitment by both organizations to address healthcare challenges and improve the quality of care while managing costs effectively. The partnership is based on a press release statement and reflects the ongoing trend in healthcare towards integrating advanced technologies to streamline operations and enhance patient care.

In other recent news, Philips, the healthcare technology company, has seen an increase in stakes by Artisan Investments, a U.S. asset management firm. The firm's stake in Philips has risen to 10%, making it the second-largest shareholder after Exor (AS:EXOR). This development comes after Philips reported an 8% rise in its adjusted earnings before interest, taxes, and amortization (EBITA) to €388 million ($417.22 million).

Philips also announced a smaller-than-expected settlement related to the resolution of claims in the U.S. over recalled breathing devices. Moreover, the company's first-quarter results showed a 2.4% increase in comparable sales and improved margins. Philips has also made significant strides in addressing the Respironics recall, which includes a consent decree and court-approved settlements.

In their First Quarter 2024 Results Conference Call, Philips expressed optimism about its 2024 outlook, expecting 3-5% sales growth and an adjusted EBITDA margin of 11-11.5%. The free cash flow forecast for 2024 has been revised to EUR 0.9 billion to EUR 1.1 billion. These are the recent developments in the operations of Philips.

InvestingPro Insights

As Royal Philips embarks on a significant partnership with Bon Secours Mercy Health to revolutionize patient monitoring, investors and stakeholders may find it pertinent to consider the company's financial health and market performance. Philips' aggressive share buyback strategy signals a confident outlook from management, aligning with the strategic moves to expand and innovate within the healthcare industry.

InvestingPro data indicates that Philips has a market capitalization of $24.08 billion, underscoring its substantial presence in the market. Despite recent challenges reflected in a negative P/E ratio of -27.17, analysts forecast a turnaround with net income expected to grow this year. This anticipated profitability, coupled with a strong free cash flow yield implied by its valuation, suggests potential for robust financial performance ahead.

With a 33.34% return over the last three months, Philips' stock has shown resilience and an upward trajectory. This performance is particularly noteworthy given the company's role as a prominent player in the Healthcare Equipment & Supplies industry. Investors may also be encouraged by the fact that Philips does not pay a dividend, which could imply a strategic reinvestment of earnings back into the company's core growth initiatives.

For those seeking to delve deeper into Philips' financial prospects and strategic position, additional InvestingPro Tips are available, offering insights such as the company's high EBIT and EBITDA valuation multiples, and the prediction that Philips will be profitable this year. To access these insights and more, visit https://www.investing.com/pro/PHG and consider using the coupon code PRONEWS24 to get up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription. In total, there are 10 InvestingPro Tips available for Philips, providing a comprehensive analysis for informed investment decisions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.